



Universiteit
Leiden
The Netherlands

Concepts and applications for evidence-based dosing in morbidly obese patients before and after weight loss surgery

Brill, Margreke Jantine Eltje

Citation

Brill, M. J. E. (2015, December 3). *Concepts and applications for evidence-based dosing in morbidly obese patients before and after weight loss surgery*. Retrieved from <https://hdl.handle.net/1887/36511>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/36511>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/36511> holds various files of this Leiden University dissertation


Author: Brill, Margreke

Title: Concepts and applications for evidence-based dosing in morbidly obese patients before and after weight loss surgery

Issue Date: 2015-12-03

CHAPTER 1

Introduction, scope and
outline of the investigations



MORBID OBESITY

The prevalence of obesity (body mass index, BMI > 30 kg/m²) and morbid obesity (BMI > 40 kg/m²) is increasing across the globe^{1,2}. Mexico and the US seem to deal with the highest obesity prevalence rates among adults, 32% and 35% respectively^{1,3}, while the estimated obesity prevalence rates for 2013 show that >50% of the women in Kuwait, Libya and Qatar are obese⁴. The average prevalence of obesity in Europe is estimated between 18-21% in 2013. In the Netherlands approximately 35% of the population is overweight (BMI > 25 kg/m²) and 13% obese⁵. Numbers of morbid obesity in Europe are lacking, but are estimated to range between 1-7% depending on the country⁵⁻⁸. A global analysis of overweight and obesity prevalence rates suggests that in developed countries the increasing obesity trend has attenuated over the past 8 years, while in the developing world the trend seems to continue to increase⁴.

With obesity and morbid obesity, physiologic parameters may alter. These patients are reported to have a lower percentage of fat free mass and water relative to their total body weight⁹⁻¹⁰, while absolute values of cardiac output and blood volume are increased in comparison to non-obese subjects¹¹. Concerning liver function, non-alcoholic steatohepatitis is highly associated with morbid obesity patients and histological liver abnormalities such as fatty infiltration are present in approximately 90% of the livers of this population¹²⁻¹³. Furthermore, liver perfusion may be altered due to a combination of ballooning of hepatocytes (due to fatty infiltration) and narrowing of the peripheral hepatic micro vessels, the sinusoids¹⁴. For renal function, it seems that in obese subjects creatinine clearance increases with fat free mass¹⁵ and glomerular filtration is increased in overweight and obese subjects compared to non-obese subjects¹⁶⁻¹⁷.

In addition, it has been reported that obese patients have an increased risk to develop, among others, thrombosis¹⁸, cardiovascular disease¹⁹, cancer²⁰, and infections, including surgical site infections and other nosocomial infections as well as to develop serious complications of common infections²¹. The underlying causes of this increased risk are thought to be related to the metabolic syndrome and the increased inflammation status which are both highly prevalent among subjects with (morbid) obesity²²⁻²⁴.

The physiological changes in obese and morbidly obese patients mentioned above may impact the pharmacokinetics and pharmacodynamics of drugs. Therefore evidence-based dosing guidelines in the (morbidly) obese population are needed, as this population deserves to receive effective and safe pharmacotherapy as much as any other patient group. In particular, in view of the increased risk of obese patients to serious comorbidities, evidence-based dosing is necessary. To reach this goal, knowledge on the extent into which these physiologic changes influence absorption, metabolism, distribution and elimination of drugs is essential. Ultimately also the influence of obesity on the pharmacokinetic-pharmacodynamic relationship should be evaluated.

In the past decades a substantial number of studies have aimed to evaluate how the pharmacokinetics of certain drugs change in obese patients. However, it seems that in the vast majority of these studies only overweight ($\text{BMI} > 25 \text{ kg/m}^2$) and obese ($\text{BMI} > 30 \text{ kg/m}^2$) subjects were included, while today morbidly obese patients ($\text{BMI} > 40 \text{ kg/m}^2$) are not uncommon in the daily practice of physicians and pharmacists. In this respect, there is a strong need for pharmacokinetic studies after both intravenous and oral drug administration in morbidly obese patients to establish evidence-based dosing guidelines for this special population.

BARIATRIC SURGERY

Bariatric surgery or weight loss surgery is considered the most effective treatment option for morbid obesity²⁵⁻²⁶ and results, among other factors, in long term weight loss, reduction in overall mortality and remission of type 2 diabetes²⁶⁻²⁷. Adult patients with a $\text{BMI} > 40 \text{ kg/m}^2$ or with a $\text{BMI} > 35 \text{ kg/m}^2$ with a severe obesity-related co morbid condition such as hypertension, impaired glucose tolerance, diabetes mellitus, hyperlipidemia, or obstructive sleep apnea qualify for a bariatric surgery procedure²⁸⁻²⁹. Bariatric surgery comprises of many different types of surgery of which the Roux and – Y gastric bypass (RYGB, 47% in 2011) and sleeve gastrectomy (SG, 28% in 2011) are currently most performed worldwide, while the adjustable gastric banding procedure has not been performed much in recent years (18% in 2011)³⁰. During a Roux and – Y gastric bypass the stomach is reduced to a small pouch and the duodenum and initial part of the small intestine are bypassed³¹⁻³². For a sleeve gastrectomy a large portion of the stomach along the greater curvature is removed resulting in a tube like structure along the smaller curvature³³. The prevalence of bariatric surgery is increasing, with more than 340,000 bariatric surgeries performed worldwide in 2011³⁰. For the Netherlands, the media reported a significant increase in bariatric surgeries from 4,000 in 2011 to an estimate of 10,000 in 2013³⁴.

Bariatric patients present physicians and pharmacists with many challenges regarding safe and effective drug therapy, as bariatric procedures may impact a drug's pharmacokinetics both due to the anatomical changes made to the gastro-intestinal tract and the induced loss in body weight. These anatomical changes may cause an increase in stomach pH, an increase in gastric emptying time, and a decrease in the surface area of absorption^{31,35}, thus potentially affecting a drug's rate and extent of oral absorption. In addition to these anatomical alterations, bariatric patients may lose a substantial percentage of their body weight (a mean of 32% of total body weight 0.5-2 years after bariatric surgery²⁶) which may have a major impact on the distribution and clearance of a drug³⁶.

While case reports have reported a decrease in oral drug exposure of certain drug in patients after bariatric surgery (e.g. tamoxifen ³⁷, phenytoin ³⁸, imatinib ³⁹), so far only 17 clinical studies have aimed to evaluate how a bariatric procedure alters the pharmacokinetics of approximately 25 drugs ^{31, 36, 40}. The results of this limited number of studies show a large variation. For some drugs, mean oral absorption remains unchanged after a gastric bypass as measured by the oral AUC (e.g. atorvastatin ⁴¹, furosemide and omeprazole ⁴²), while others, including erythromycine ⁴³, tacrolimus and sirolimus ⁴⁴ and tolbutamide ⁴², showed a substantial reduction in AUC after an oral dose. In contrast, for metformin an increase in oral AUC was reported in 16 patients after RYGB ⁴⁵. In summary, there seems to be a large variation in how bariatric surgery influences drug exposure after oral administration ³⁶, whereas it seems that this variation cannot be related to the Biopharmaceutics Classification System (BCS) ⁴⁶. Alternatively, the impact of bariatric surgery on the absorption of a specific drug may be predicted based on the type of surgery and knowledge of the involved absorption processes of the drug (e.g. availability of transporters, bile salts, main oral absorption site, CYP3A substrate, etc.). However, due to the small number of studies, the limited number of patients included, the large variation in compounds studied and types of bariatric surgery included in these studies, no such conclusion can be derived yet.

Finally, information on how loss in body weight in morbidly obese patients after bariatric surgery affects the pharmacokinetics of drugs has only been studied for 8 drugs ^{42, 45, 47-48}, while it is known that increase in body weight greatly affects clearance and particularly distribution of drugs.

THE OBJECTIVE OF THIS THESIS

There is a strong need for knowledge on safe and effective pharmacotherapy in morbidly obese patients and in addition, in patients which have undergone a bariatric procedure.

As a first step towards evidence-based dosing strategies in morbidly obese patients, **Chapter 2** presents an overview of studies on drug pharmacokinetics including both obese and non-obese subjects, sorted by metabolic or elimination pathway of the drug. This overview shows that the impact of obesity on drug metabolism and elimination seems to differ greatly between drugs and depends on the metabolic or elimination pathway primarily involved in the clearance of a drug. In addition, obesity may also impact oral absorption, oral bioavailability and the volume of distribution of drugs. **Chapter 3** provides an overview of the impact of obesity on absorption, distribution, metabolism and elimination of drugs as well as perspectives for future research into the influence of obesity on pharmacokinetics. It shows that (morbid) obesity may largely impact volume of distribution, while the magnitude and direction of change are difficult

to predict, while changes in clearance may be smaller than those on volume of distribution and may be predictable on the basis of the elimination pathway involved. Lastly, it describes that very little is known about the influence of obesity on oral absorption.

The clinical studies presented in this thesis focused on two drugs, i.e. cefazolin and midazolam. In **Chapter 4** a study is presented which aimed to evaluate the influence of morbid obesity on cefazolin pharmacokinetics and penetration into the subcutaneous tissue using clinical microdialysis techniques. Cefazolin is a first generation cephalosporin antibiotic which is widely applied for the prevention of surgical site infections during many types of surgical interventions, including bariatric surgery⁴⁹ and is eliminated completely by glomerular filtration and active tubular excretion⁵⁰. It was studied because in morbidly obese patients there seem to be more surgical wound infections, while cefazolin plasma concentrations seem to reach adequate levels^{21, 51}. It was unknown whether cefazolin reaches adequate levels at the target site, which is the subcutaneous adipose tissue around the surgical wounds, in morbidly obese patients..

Chapter 5 presents a study of midazolam population pharmacokinetics in morbidly obese patients. Midazolam was studied because it is the best Cytochrome P450 3A (CYP3A) substrate currently available and preliminary evidence indicates that absolute clearance of CYP3A substrates is lower in obese patients (Chapter 2)⁵². Midazolam is a widely applied drug for sleeping disorders, (pre)anesthesia and sedation in the Intensive Care. It is metabolized into 1-OH-midazolam by the CYP3A enzyme and is considered a model probe for the activity of CYP3A⁵³⁻⁵⁴. CYP3A is an important enzyme system that is involved in the metabolism of 25% of all clinically used drugs⁵⁵, including many drugs that are relevant for obese patients, such as statins, cardiovascular drugs, antipsychotics and oncolytic drugs⁵⁶. A potentially reduced absolute clearance is highly relevant, because it may result in prolonged effect of the drug with increased risk of adverse events particularly upon prolonged use. As the CYP3A enzyme is located in the liver as well as in the gut wall, it determines both systemic clearance and oral drug bioavailability of CYP3A substrates including midazolam. For this reason a semi-simultaneous dosing design was applied in this study, in which patients first received an oral dose followed by an intravenous dose approximately 150 minutes later. This design allowed for both the evaluation of systemic midazolam clearance as well as midazolam oral bioavailability.

The influence of bariatric surgery on the pharmacokinetics of midazolam was studied in **Chapter 6**. In this study, eighteen patients of the morbidly obese patients who participated in the study of Chapter 5 were restudied one year post bariatric surgery using the same study design. Midazolam systemic clearance and oral bioavailability were closely studied in view of anticipated weight loss together with the anatomical changes to the gastro-intestinal tract, respectively.

To further investigate the CYP3A mediated metabolism of midazolam into 1-OH-midazolam, in **Chapter 7** we used midazolam and 1-OH-midazolam data and semi-phys-

iologically based PK modeling to quantify the influence of bariatric surgery on CYP3A activity in the gut wall and liver separately. This evaluation required a more advanced model in which also presystemic metabolism of midazolam into 1-OH-midazolam could be accounted for.

In **Chapter 8**, the outcomes of the Chapters 4-7 are summarized and interpreted. In addition, perspectives on future studies and directions for evidence-based dosing guidelines in morbidly obese and bariatric patients are provided with the latter being particularly of relevance for clinical practice. Finally, the relevance of these findings for other drugs which share the same elimination pathway are discussed.

REFERENCES

1. IOTF. International Obesity Taskforce. In.
2. Finkelstein EA, Khavjou OA, Thompson H, et al. Obesity and severe obesity forecasts through 2030. *Am J Prev Med* 2012;42:563-70.
3. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. *Jama*;303:235-41.
4. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 2014;384:766-81.
5. Blokstra A, Vissink P, Venmans LMAJ, Hollemans P, Van Der Schouw YT. Nederland de Maat Gemenen, 2009-2010 Monitoring van risicofactoren in de algemene bevolking: Rijksinstituut voor Volksgezondheid en Milieu (RIVM); 2011.
6. Hautvast J. Overgewicht en obesitas: Health Council of the Netherlands; April 28, 2003.
7. Craig R, Mindell J, al. e. Cardiovascular disease and risk factors in adults. London: The Information Centre for Health and Social Care: Health Survey for England 2006; 2008.
8. Andreyeva T, Michaud PC, van Soest A. Obesity and health in Europeans aged 50 years and older. *Public Health* 2007;121:497-509.
9. Cheymol G. Clinical pharmacokinetics of drugs in obesity. An update. *Clin Pharmacokinet* 1993; 25:103-14.
10. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. *Clin Pharmacokinetics* 2000;39:215-31.
11. Alexander JK, Dennis EW, Smith WG, Amad KH, Duncan WC, Austin RC. Blood volume, cardiac output, and distribution of systemic blood flow in extreme obesity. *Cardiovasc Res Cent Bull* 1962;1:39-44.
12. Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. *Best Pract Res Clin Gastroenterol* 2014;28:637-53.
13. Moretto M, Kupski C, Mottin CC, et al. Hepatic steatosis in patients undergoing bariatric surgery and its relationship to body mass index and co-morbidities. *Obes Surg* 2003;13:622-4.
14. Brock RW, Dorman RB. Obesity, insulin resistance and hepatic perfusion. *Microcirculation* 2007; 14:339-47.
15. Salazar DE, Corcoran GB. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. *Am J Med* 1988;84:1053-60.
16. Ribstein J, du Cailar G, Mimran A. Combined renal effects of overweight and hypertension. *Hypertension* 1995;26:610-5.
17. Stokholm KH, Brochner-Mortensen J, Hoilund-Carlsen PF. Increased glomerular filtration rate and adrenocortical function in obese women. *Int J Obes* 1980;4:57-63.
18. Blokhin IO, Lentz SR. Mechanisms of thrombosis in obesity. *Curr Opin Hematol* 2013;20:437-44.
19. Fan J, Song Y, Chen Y, Hui R, Zhang W. Combined effect of obesity and cardio-metabolic abnormality on the risk of cardiovascular disease: a meta-analysis of prospective cohort studies. *Int J Cardiol* 2013;168:4761-8.
20. Ligibel JA, Alfano CM, Courneya KS, et al. American Society of Clinical Oncology position statement on obesity and cancer. *J Clin Oncol* 2014;32:3568-74.
21. Falagas ME, Kompoti M. Obesity and infection. *Lancet Infect Dis* 2006;6:438-46.

22. Wildman RP, Muntner P, Reynolds K, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). *Arch Intern Med* 2008;168:1617-24.
23. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. *J Clin Invest* 2005;115:1111-9.
24. Mathieu P, Lemieux I, Despres JP. Obesity, inflammation, and cardiovascular risk. *Clin Pharmacol Ther* 2010;87:407-16.
25. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. *JAMA* 2004;292:1724-37.
26. Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. *N Engl J Med* 2004;351:2683-93.
27. Sjostrom L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. *JAMA* 2014;311:2297-304.
28. Fried M, Hainer V, Basdevant A, et al. Interdisciplinary European guidelines for surgery for severe (morbid) obesity. *Obes Surg* 2007;17:260-70.
29. Heelkunde NVv. RICHTLIJN MORBIDE OBESITAS. Utrecht; 2011
30. Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2011. *Obes Surg* 2013;23:427-36.
31. Edwards A, Ensom MH. Pharmacokinetic effects of bariatric surgery. *Ann Pharmacother* 2012;46:130-6.
32. Kral JG, Naslund E. Surgical treatment of obesity. *Nat Clin Pract Endocrinol Metab* 2007;3:574-83.
33. Baltasar A, Serra C, Perez N, Bou R, Bengochea M, Ferri L. Laparoscopic sleeve gastrectomy: a multi-purpose bariatric operation. *Obes Surg* 2005;15:1124-8.
34. Weeda F. Aantal maagverkleiningen neemt explosief toe. *NRC Handelsblad* 2014, June 3.
35. Horner KM, Byrne NM, Cleghorn GJ, Naslund E, King NA. The effects of weight loss strategies on gastric emptying and appetite control. *Obes Rev* 2011;12:935-51.
36. Brocks DR, Ben-Eltriki M, Gabr RQ, Padwal RS. The effects of gastric bypass surgery on drug absorption and pharmacokinetics. *Expert Opin Drug Metab Toxicol* 2012;8:1505-19.
37. Wills SM, Zekman R, Bestul D, Kuwajerwala N, Decker D. Tamoxifen malabsorption after Roux-en-Y gastric bypass surgery: case series and review of the literature. *Pharmacotherapy* 2010;30:217.
38. Pournaras DJ, Footitt D, Mahon D, Welbourn R. Reduced phenytoin levels in an epileptic patient following Roux-En-Y gastric bypass for obesity. *Obes Surg* 2011;21:684-5.
39. Pavlovsky C, Egorin MJ, Shah DD, Beumer JH, Rogel S, Pavlovsky S. Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia. *Pharmacotherapy* 2009;29:1152-6.
40. Sawaya RA, Jaffe J, Friedenberg L, Friedenberg FK. Vitamin, mineral, and drug absorption following bariatric surgery. *Curr Drug Metab* 2012;13:1345-55.
41. Skottheim IB, Stormark K, Christensen H, et al. Significantly altered systemic exposure to atorvastatin acid following gastric bypass surgery in morbidly obese patients. *Clin Pharmacol Ther* 2009;86:311-8.
42. Tandra S, Chalasani N, Jones DR, Mattar S, Hall SD, Vuppalanchi R. Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. *Ann Surg* 2013;258:262-9.
43. Prince RA, Pincheira JC, Mason EE, Printen KJ. Influence of bariatric surgery on erythromycin absorption. *J Clin Pharmacol* 1984;24:523-7.
44. Rogers CC, Alloway RR, Alexander JW, Cardi M, Trofe J, Vinks AA. Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study. *Clin Transplant* 2008;22:281-91.

45. Padwal RS, Gabr RQ, Sharma AM, et al. Effect of gastric bypass surgery on the absorption and bioavailability of metformin. *Diabetes Care* 2011;34:1295-300.
46. Darwich AS, Henderson K, Burgin A, et al. Trends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classes. *Br J Clin Pharmacol* 2012;74:774-87.
47. Lloret-Linares C, Hirt D, Bardin C, et al. Effect of a Roux-en-Y gastric bypass on the pharmacokinetics of oral morphine using a population approach. *Clin Pharmacokinet* 2014;53:919-30.
48. De Smet J, Colin P, De Paepe P, et al. Oral bioavailability of moxifloxacin after Roux-en-Y gastric bypass surgery. *J Antimicrob Chemother* 2012;67:226-9.
49. Bratzler DW, Dellinger EP, Olsen KM, al. e. Clinical practice guidelines for antimicrobial prophylaxis in surgery. *Am J Health-Syst Pharm* 2013;70:195-283.
50. Nightingale CH, Greene DS, Quintiliani R. Pharmacokinetics and clinical use of cephalosporin antibiotics. *J Pharm Sci* 1975;64:1899-926.
51. van Kralingen S, Taks M, Diepstraten J, et al. Pharmacokinetics and protein binding of cefazolin in morbidly obese patients. *Eur J Clin Pharmacol* 2011;67:985-92.
52. Brill MJ, Diepstraten J, van Rongen A, van Kralingen S, van den Anker JN, Knibbe CA. Impact of obesity on drug metabolism and elimination in adults and children. *Clin Pharmacokinet* 2012;51:277-304.
53. Streetman DS, Bertino JS, Jr., Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. *Pharmacogenetics* 2000;10:187-216.
54. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. *Biochem Pharmacol* 1994;47:1643-53.
55. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. *Pharmacol Ther* 2013;138:103-41.
56. Cytochrome P450 Drug Interaction Table. (Accessed at <http://www.greenbridgemed.com/wp-content/uploads/2011/09/Drugs-using-P450-Hepatic-metabolism.pdf>.)

